Use of risk stratification to target therapies in patients with recent onset arthritis; Design of a prospective randomized multicenter controlled trial by Claessen, S.J.J. (Susanne) et al.
BioMed CentralBMC Musculoskeletal Disorders
ssOpen AcceStudy protocol
Use of risk stratification to target therapies in patients with recent 
onset arthritis; design of a prospective randomized multicenter 
controlled trial
Susanne JJ Claessen1, Johanna MW Hazes1, Margriet AM Huisman2, 
Derkjen van Zeben2, Jolanda J Luime1 and Angelique EAM Weel*1,3
Address: 1Department of Rheumatology, Erasmus MC, University Medical Center, Dr Molewaterplein, Rotterdam, The Netherlands, 2Department 
of Rheumatology, Sint Franciscus Gasthuis, Kleiweg, Rotterdam, The Netherlands and 3Department of Rheumatology, Maasstad Ziekenhuis, 
Olympiaweg, Rotterdam, The Netherlands
Email: Susanne JJ Claessen - s.claessen@kaze.nl; Johanna MW Hazes - j.hazes@erasmusmc.nl; Margriet AM Huisman - m.huisman@sfg.nl; 
Derkjen van Zeben - j.vanzeben@sfg.nl; Jolanda J Luime - j.luime@erasmusmc.nl; Angelique EAM Weel* - weela@maasstadziekenhuis.nl
* Corresponding author    
Abstract
Background: Early and intensive treatment is important to inducing remission and preventing joint damage in
patients with rheumatoid arthritis. While intensive combination therapy (Disease Modifying Anti-rheumatic Drugs
and/or biologicals) is the most effective, rheumatologists in daily clinical practice prefer to start with monotherapy
methotrexate and bridging corticosteroids. Intensive treatment should be started as soon as the first symptoms
manifest, but at this early stage, ACR criteria may not be fulfilled, and there is a danger of over-treatment. We
will therefore determine which induction therapy is most effective in the very early stage of persistent arthritis.
To overcome over-treatment and under-treatment, the intensity of induction therapy will be based on a
prediction model that predicts patients' propensity for persistent arthritis.
Methods: A multicenter stratified randomized single-blind controlled trial is currently being performed in
patients 18 years or older with recent-onset arthritis. Eight hundred ten patients are being stratified according to
the likelihood of their developing persistent arthritis. In patients with a high probability of persistent arthritis, we
will study combination Disease Modifying Antirheumatic Drug therapy compared to monotherapy methotrexate.
In patients with an intermediate probability of persistent arthritis, we will study Disease Modifying Antirheumatic
Drug of various intensities. In patients with a low probability, we will study non-steroidal anti-inflammatory drugs,
hydroxychloroquine and a single dose of corticosteroids. If disease activity is not sufficiently reduced, treatment
will be adjusted according to a step-up protocol. If remission is achieved for at least six months, medication will
be tapered off. Patients will be followed up every three months over two years.
Discussion: This is the first rheumatological study to base treatment in early arthritis on a prediction rule.
Treatment will be stratified according to the probability of persistent arthritis, and different combinations of
treatment per stratum will be evaluated. Treatment will be started early, and patients will not need to meet the
ACR-criteria for rheumatoid arthritis.
Trial registration: This trial has been registered in Current Controlled Trials with the ISRCTN26791028.
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Rheumatoid arthritis (RA) is a chronic inflammation of
the joints that causes structural joint damage, affecting
daily physical functioning and often limiting social func-
tioning and work participation. [1-7] Its prevalence in
Europe is around 1%.[8] Although its primary cause is
unknown, multiple genetic and environment factors seem
to be involved.[9] While no cure has been found, combi-
nations of disease-modifying anti-rheumatic drugs
(DMARDs) and biologicals have proved very effective in
reducing disease activity and radiological progression,
especially when given early in the disease course. [10-22]
The studies to have reported this were all performed in
patients who fulfilled the ACR criteria of RA. But if the
treatment of RA is to be improved, it is necessary to go
beyond the ACR criteria, a number of which apply to fea-
tures of later stages of the disease, and are thus insensitive
in early rheumatoid arthritis.[23]
The need for earlier treatment is recognized by the EULAR,
who recommend not only that "patients at risk of devel-
oping persistent or erosive arthritis should be started with
DMARDs as early as possible, even if they do not yet fulfil
established classification criteria for inflammatory rheu-
matological diseases," but also "among the DMARDS,
methotrexate is considered to be the anchor drug, and
should be used first in patients at risk of developing per-
sistent disease."[24] However, it is unclear which criteria
should be used for the early identification of persistent
disease.
One way of identifying patients at risk for persistent dis-
ease would be by using early arthritis-prediction mod-
els[25,26], none of which have yet been used for
treatment decisions in daily practice. Visser et al devel-
oped a prediction rule with seven factors: 1.) symptom
duration at the first visit, 2.) morning stiffness for at least
one hour, 3.) arthritis in three or more joints, 4.) bilateral
compression pain in the MTP joints, 5.) IgM-RF positivity,
6.) anti-CCP positivity, and 7.) erosions on radiographs of
the hands or feet. The odds ratio (OR) of each variable was
simplified by substituting the ORs with weighted scores
from 0 to 13 points. The range of probabilities to which
this translated lay between a 10% probability of develop-
ing persistent arthritis when one point was scored, and a
99% probability when 13 points were scored. Greater
detail is available in Visser et al.[26]
The main aim of the present study is to determine which
prediction-guided treatment strategy is superior in
patients with recent-onset arthritis who, on the basis of
the Visser Prediction rule, are stratified as having a low,
intermediate or high risk of developing persistent arthri-
tis.
Methods
Study design
The Treatment in the Rotterdam Early Arthritis Cohort
(tREACH) is a multicenter stratified randomized single-
blind controlled trial. Patients aged ≥ 18 years with at least
one arthritis (symptom duration less than one year) will
be invited to participate. After providing written informed
consent, eligible patients will be stratified into three
groups according to the likelihood (on the basis of the
prediction model of Visser described previously) of their
progressing to persistent arthritis. Patients in each stratum
will be randomized to three treatment strategies (a so-
called 3 × 3 design). Variable block randomization will be
accomplished by a coordination center by telephone dur-
ing working hours. Treatment strategy will be predefined
for the first year, after which the rheumatologist will be
free to prescribe as they see fit. Follow-up will take place
every three months over a period of two years.
Recruitment
Patients are currently being recruited from a large prospec-
tive cohort study, the Rotterdam Early Arthritis Cohort
(REACH study). This includes patients aged ≥ 16 years
who live in the area of Rotterdam and have inflammatory
joint complaints whose symptoms they have had for less
than one year. The REACH study is being conducted in
cooperation with the general practitioners in the
region.[3,5]
To be included in the present study, patients should have
had at least one arthritis confirmed by a rheumatologist.
They will be excluded 1.) if they are were diagnosed with
a crystal arthropathy, infectious or post-infectious arthri-
tis, or an autoimmune rheumatic disorder other than RA;
2.) if they have been on DMARD therapy, corticosteroids
within the last three months, or on concomitant treat-
ment with any experimental drug; or 3.) if there are any of
the following: contra-indications for the initial study
medication (history of chronic liver disease; excessive
alcohol and drug use; pregnancy or the desire to become
pregnant during the study; childbearing potential without
adequate contraception; or the following laboratory
abnormalities: leucopenia (< 3.0 × 109/l), thrombocyto-
penia (< 150 × 109/l), ASAT/ALAT > double the upper nor-
mal value creatinine level > 150 μmol/l).
Interventions
The medical interventions evaluated in tREACH include
three conventional DMARDs: methotrexate (MTX), sul-
fasalazine (SSZ) and hydroxychloroquine (HCQ). Since
intensive treatment is important early in the disease
course, this trial is designed to produce the greatest treat-
ment differences during the first three months of therapy
(induction therapy).Page 2 of 8
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uated per probability stratum:
1. A high-probability group (HP), in which the risk of
developing persistent arthritis is >70%
2. An intermediate-probability group (IP), in which
this risk lies between 30% and 70%
3. A low-probability group (LP), in which this risk is <
30%
Treatment strategies will be tightly controlled, with
patients being examined every three months.[27] The aim
of treatment is to reduce disease activity as expressed by
the Disease Activity Score (DAS) ≤ 2.4.[28] If initial treat-
ment fails (DAS>2.4), the treatment will be intensified
using the next step of the prescribed treatment strategy. If
the DAS ≤ 2.4, initial treatment will be continued; if the
patient meets the criteria for remission (DAS ≤ 1.6) over
three successive visits, it will be tapered off. If there is a
discrepancy between the DAS score and the opinion of the
rheumatologist, an additional DAS will be performed two
weeks later. If the discrepancy persists, the initial DAS will
be used.
Induction therapy
Figures 1, 2 and 3 show the the types, dosages of induc-
tion and step-up therapy for the three probability groups.
In the HP group, the three induction therapies are:
• Combination DMARD (MTX, SSZ and HCQ) ther-
apy with single-dose corticosteroids intramuscularly
• Combination DMARD (MTX, SSZ and HCQ) ther-
apy with cumulative high-dose corticosteroids
• MTX with cumulative high-dose corticosteroids
Medication strategies in the high-probability groupFigure 1
Medication strategies in the high-probability group. Dosages: MTX: 25 mg/week oral or subcutaneously. SSZ: 2 grams/
day. HCQ: 200 mg twice a day. Single-dose corticosteroids intramuscularly: kenacort 80 mg once intramuscularly, or depome-
drol 120 mg once intramuscularly. Prednisone scheme: Week 1–4 15 mg a day. Week 5–6: 10 mg a day. Week 7–8: 5 mg a day. 
Week: 9–10: 2.5 mg a day. Etanercept: 50 mg once a week subcutaneously. Adalumimab: 40 mg once every two weeks subcu-
taneously. Rituximab: 1 gram intravenously, repeated after two weeks. Leflunomide: 20 mg once daily.
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(risedronate 35 mg once a week; combination of calcium
and vitamin D 500/440) will be given to patients who are
treated with cumulative high-dose corticosteroids during
induction therapy.
In the IP group, the three induction therapies are:
• MTX
• Cumulative high-dose corticosteroids
• HCQ
In the LP group, the three induction therapies are:
• Naproxen
• Single-dose corticosteroids intramuscularly
• HCQ
Treatment failure (DAS > 2.4)
If DAS>2.4, the DAS will be measured every three months,
and treatment will be intensified by step-up therapy
according to the next step of the treatment protocol (fig-
ure 1, 2 and 3).
For patients in the HP group step-up therapy will be the
combination of MTX and anti-TNF α (Etanercept), if ther-
apy still fails after 3 months patients will be switched to
another anti-TNF α (Adalumimab). [29-31] The final
step-up will be B-cell depletion (Rituximab).
The initial step-up in the IP group and LP group will be
the combination DMARDs (MTX-SSZ-HCQ). If failure
persists treatment will be intensified to the combination
of MTX and anti-TNF α (Etanercept), and finally to
another anti-TNF α (Adalumimab).
Disease remission (DAS ≤ 1.6)
In all probability, if remission (DAS ≤ 1.6) is achieved
over three consecutive visits, a group's medication will be
tapered off. Step-down of therapy in patients using the
combination of MTX-SSZ-HCQ will start with tapering
SSZ in the first three months, followed, if this is successful,
Medication strategies in the intermediate probability groupFigure 2
Medication strategies in the intermediate probability group. Dosages: see figure 1 legend.
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will be stopped. If patients using the combination of MTX
and anti-TNF α achieve remission, first the anti-TNF will
be stopped and, if remission sustained, MTX is finally
stopped. Patients achieving remission during B-cell deple-
tion therapy, first of all B-cell depletion will be stopped
and if this is successful, MTX will be tapered off.
Drug side-effects and concomitant drugs
In the event of side effects or contra-indications for the
study medication, patients will be treated with lefluno-
mide 20 mg 1 dd. During follow-up, Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs) and intra-articular injec-
tions will be allowed. Safety monitoring of treatment will
take place according to Dutch guidelines.
Data collection
The primary outcome parameters are functional ability
(HAQ), disease activity (DAS), and radiological joint
damage (the modified Sharp van der Heijde score (modi-
fied SvH)).
The HAQ is a self-report functional status measure assess-
ing eight activities 1.) dressing and grooming, 2.) arising,
3.) eating, 4.) walking, 5.) hygiene, 6.) reaching, 7.) grip-
ping, and 8.) common daily activities.[32] For each of
these categories, patients report the amount of difficulty
they have performing two or three specific activities. The
HAQ score is 0–3 with a minimal clinically important dif-
ference of 0.22.
The DAS includes the Ritchie articular index, the 44 swol-
len joint count, the Erythrocyte Sedimentation Rate, and a
general health assessment on a VAS.[28] The DAS ranges
between 0 and 10.
The modified SvH score will be used to determine the
extent of joint damage.[33] Single-emulsion radiographs
of the hands (posteroanterior view) and feet (anteropos-
terior view) will be obtained and digitized for blinded
reading. Two independent blinded readers will score the
radiographs of each patient by assessing joint erosions (0–
5 scale) and joint-space narrowing (0–4 scale) per joint.
Medication strategies in the low-probability groupFigure 3
Medication strategies in the low-probability group. Dosages: see figure 1 legend. NSAID: Naproxen 1000 mg/day.
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X-ray data will be collected every six months over two
years of follow-up.
Secondary outcome parameters will include 1.) WHO/
ILAR and EULAR Core-set measurements for clinical trials
[34,35], 2.) self-assessed disease activity (RADAI)[36],
and 3.) Quality of life on the basis of the SF-36 and the
Euroqol [37,38].
Using self-reported questionnaires and chart data, addi-
tional data will be collected on direct and indirect health-
care costs, and adverse and seriously adverse events.
Data monitoring and ethical approval
This study is being monitored by a steering committee. To
verify the data, the study coordinator, a member of the
steering committee, will visit the participating centers fre-
quently. All patient data collected during the study will be
analyzed and documented according to Good Clinical
Practice.
Ethical approval has been obtained from the Ethics Com-
mittees at Erasmus Medical Center, Sint Franciscus
Gasthuis, Maasstad Hospital, Vlietland Hospital, Albert
Schweitzer Hospital, The Oosterschelde Hospital, Hospi-
tal Walcheren, and ZorgSaam Hospital.
Statistics
Sample size
Sample-size calculations were based on the AUC HAQ
using primary data from the BeST study[15], where the
mean AUC HAQ of the combination therapy was 7.7 (SD
5.5) and the mean AUC HAQ of monotherapy was 10.5
(SD 7.4)
To detect this difference using a significance level of α =
0.05 and a power of 80%, ninety patients are needed in
each treatment arm. This number of patients is sufficient
to detect a difference of 6.1 AUC DAS and 20% of patients
with or without radiographic progression towards base-
line (α = 0.05; power 80%).
In total, 810 patients will be needed. Allowing for a par-
ticipation rate of 80%, 1012 patients will have to be
screened, which corresponds with 337 patients in each
probability group. With seven hospitals involved, we
expect to recruit 34 eligible patients a month.
Analysis
Baseline characteristics will be presented with descriptive
statistics. Number, mean, standard deviation, and mini-
mum and maximum values will be used for continuous
data; and absolute and relative frequencies will be used
for categorical data.
Data on the primary outcomes HAQ and DAS will be ana-
lyzed per strata of probability (HP, IP and LP) over time
using the AUC (area under the curve), which is an appro-
priate method for detecting therapy difference early in the
follow-up period. Analysis will be performed using inten-
tion-to-treat analysis and per-protocol analysis. Data on
radiological progression will be analyzed using the non-
parametric Mann-Whitney U test. All data will be ana-
lyzed using STATA 9.0 and R.
Cost-effectiveness analysis
In the study, direct and indirect costs will all be consid-
ered within the one-year period following randomization.
Direct medical costs will be calculated on the basis of use
of resources within the healthcare sector. Indirect costs are
defined as the cost of production lost through illness or its
treatment.
Medication use will be recorded on the basis of the trial
medication prescribed and will be valued on the basis of
national cost prices excluding value added tax (VAT) and
markups for the acquisition and administration of medi-
cation. The use of over-the-counter medication will be
recorded through patient questionnaires. The cost of over-
the-counter medications will be calculated on the basis of
retail prices.
Adverse events and serious adverse events will be recorded
during the trial period. To estimate the average cost per
type of adverse event, scenario studies will be conducted.
Data on medical care utilization outside the hospital and
on absence from work will be collected using a patient
questionnaire that includes questions on healthcare visits,
medication, quality of life, and number of working days
lost due to joint complaints or other disorders. As a basis
for establishing the level of production losses, we will use
the average income per person by age and gender for
2008–2010.
Cost data will be analyzed per probability stratum by
comparing the three treatment groups in each stratum.
Incremental cost-effectiveness ratios will be calculated by
dividing the difference between the costs of the treatment
strategies by the difference in the DAS and HAQ. At base-
line, 6 months and 12 months, the effects of arthritis and
therapy on utility will be measured using the EQ5d.
Discussion
The overall objective of this study is to determine the most
effective induction therapy for patients with early arthritis
who are at risk of persistent arthritis. An important differ-
ence between this study and previous studies is that we are
able to start treatment before patients have fulfilled the
ACR criteria. To do so, we are being guided by the predic-Page 6 of 8
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stratify patients according to a low, intermediate or high
risk of persistent arthritis. The induction therapies we use
reflect current rheumatology practice, ranging from
NSAIDs in the low probability group to combination
DMARD therapy in the high probability group.
This study has two specific objectives focused on induc-
tion therapy in the HP group. The first is to establish
whether MTX-monotherapy is as effective as combination
DMARD therapy (MTX-SSZ-HCQ) in patients who are at
a high risk of persistent arthritis. For although established
RA combination therapy have been shown to perform bet-
ter than monotherapy in terms of reducing disease activity
and radiological progression [10-15,17,19,20], there is no
evidence in early arthritis that monotherapy MTX is as
effective as combination DMARD therapy, despite its
accepted use in daily clinical practice. Moreover all these
studies analyzing the combination of DMARDs show that
their effectiveness may have been modified by corticoster-
oids.
Therefore the second specific objective concerns the use of
corticosteroids. In daily practice corticosteroids are widely
used as bridging therapy since the maximum therapeutic
effect of DMARD will take at least three months. But until
now, it is unclear what the starting dosage should be and
for how long corticosteroids should be prescribed. We
intend to establish whether one intramuscular bolus of
prednisolone is as effective as the cumulative high dose
over three months of oral prednisolone.
Our choice of treatment in the intermediate group was
based on the 50% chance that people in this group have a
self-limiting disease, which makes overtreatment an
important issue. To be able to choose the optimal benefit-
harm ratio for these patients, we decided to include vari-
ous treatment intensities, MTX being the most intensive.
We expect single DMARD therapy to be safe, and that
overtreatment will probably be less harmful than the risk
of irreversible joint damage [39]. Furthermore, if any of
these patients goes into remission, their medication will
also be tapered off quickly.
Mild treatment options were chosen for patients in the
low probability group, hardly any of whom are expected
to progress to persistent arthritis.
The trial is being conducted in the southwestern Nether-
lands, and has been received with great enthusiasm by the
participating centers, particularly because rheumatolo-
gists there feel that it will answer very practical questions.
Because treatment choices have been made by consensus
between all participating rheumatologists, it is likely that
the results of the trial will be implemented easily in daily
practice.
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